of agreements by which brand-name drug companies pay generics to settle patent litigation and delay entering the market … of the patent" test applied by the dissent and several appellate courts — would have meant "game over" for challenges to …

position must be recognized to a category of patent strategies particularly controversial under antitrust scrutiny, i.e. patent … settlement agreements, in particular in the form of reverse payment patent settlements (also called pay-for-delay settlements … discusses the approaches to reverse payment patent settlements adopted by antitrust authorities and courts and their clashes …

The America Invents Act of 2011 (“AIA”) created a robust administrative system—the Patent Trial and Appeal Board (“PTAB …”)—for challenging the validity of granted patents. Congress determined that administrative correction of errors made in initial patent … grants could be cheaper and more scientifically accurate than district court litigation over patent validity.In terms of …

from patent protection (iii) new forms of known substances when they do not show an improvement in known efficacy and (iv … lege lata, they will outline the interpretative leeway national judges enjoy when applying their domestic patent laws. De …

Patent Settlements in the Pharmaceutical Industry under US Antitrust and EU Competition Law examines patent settlements …) competition law. The major focus is on patent settlements involving reverse payments, commonly known as "pay … comparatively how such patent settlements and various other strategies employed by the pharmaceutical industry are scrutinised by US …

We compare patent litigation cases across four European jurisdictions – Germany, France, the Netherlands, and the UK … information at the case, litigant, and patent level for patent cases filed at the major courts in the four jurisdictions. We find …